Embed Size (px)
Citation preview
1
Johnson & Johnson Innovation
Anna Gran PhD MBA
May 2015
Innovation is Critical to our Mission of Caring and Saving Lives
1. Catalyzing more value by moving earlier in the innovation chain
2. Moving a critical mass of scientific experts and deal-making
support closer to sources of innovation
3. Simplifying access and improve our ability to effectively execute
early deals
Early Stage Innovation Strategy
3
Align with the business strategies and become
the long term value driver for the organization
2002 2012 2002 2012
16%
33%
20%
50%
Top 10
Pharmaceutical
companies
Source: Medtrack; Johnson & Johnson
The Wall Street Journal
External Innovation
Percentage of drugs under development that
were initially developed at another company
0
10
20
30
40
50
60
70
Originator
MA holder
Origin of New Medicines in the EU (2010-2012)
5
Lincker H, Ziogas C, Carr M, et al. Where do new medicines originate from in the EU? Nature Reviews
Drug Discovery 2014: 13; 92-93
Pro
po
rtio
n o
f n
ew
me
dic
ine
s (
%)
28
59
21 28 27
13 17
7
Innovation is everywhere, but mostly outside of our own organization
California
London
Boston Shanghai
San Diego Israel
Innovation Center Satellite
Russia
Singapore
Australia
Japan
Proximity is Critical
7
Close to the
innovator
• Working in
proximity to
scientific innovators
• Identifying the most
promising early-
stage opportunities
• Helping to attract
innovators
to hotspots
One Chapel Place
London W1G 0BG
http://www.jnjinnovation.com/
Patrick Verheyen –
Head, London Innovation Centre
London Team Satellites: Israel & Russia
8
Jeanne Bolger, JJDC/Investor
Zeev Zehavi, JJDC/Investor
Kurt Hertogs, Platform Technologies/Incubators
Lilian Alcaraz, Medicinal Chemistry Lead
Yiu-Lian Fong, External Innovation Lead, Diagnostics
Kristof Van Emelen, Discovery Sciences
Roger Bone, Transactions
Anthony Gemmell, Transactions
Yelda Kaya, Transactions
Chris Janssen, External Innovation, Russia
Johan Verbeeck, Alliance Management
Ann Connolly, New Ventures
Daniel Janse, New Ventures
Rit Boeckx, Office Manager
Lily Cortese, Project Management
Laurent Morlet, Information Technology
Ellen Rose, Communication & External Affairs
Iqbal Hussain, Legal Affairs
Mohit Vatsa, Finance
THERAPEUTIC AREA LEADS
Immunology Oncology CV
Metabolic
Neuroscience Microbiome
/Vaccines
Infectious
Disease
Consumer Medical
Device
Ian Anderson
Louise
Jopling
Omid Vafa
Karin
Conde-
Knape
Declan
Jones
Anthony
Williamson
Kenny
Simmen
Elena
Fernandez-
Kleinlein
Amir
Babaei-
Mahani
Extending Our Network through Satellites and Scouts
• Dedicated presence in
Israel and Russia
• Teaming up with local
J&J colleagues to
extend coverage in
several European
countries
• Scanning for
opportunities and
liaising with biotech &
academia and
maintaining
interactions with
partner organizations
(Israel)
10
1
0
Transformational
Idea
Right Solution – JLABS
– Advice + Mentorship
– Incubation & Seed
Financing
– Venture Financing
– Investment Partners
– Strategic LP
Relationships
– R&D Collaborations
– Soft and Call Options
– Licensing
– Acquisition
With our combined
resources, how can
we work together to
bring the idea to the
next stage of its
development?
Custom Collaboration Solutions to Meet the Unique Needs of Each Innovation
Assess Options
11 CONFIDENTIAL: For internal use only
Cardiovascular & Metabolism
Immunology
Infectious Diseases & Vaccines
Neuroscience
Oncology
General Surgery
Biosurgery
Orthopedics
Vision Care
Infection Care
Diabetes
Energy
Cardiovascular
Ear, Nose, Throat
Neuroscience
Aesthetics
Well-being & beauty
Baby care
Body care
Facial skin care
Sun care
Feminine personal care
Health & Healing
Allergy care
Compromised skin
Cough & cold care
Digestive health
Oral care
Pain care
Co-creation Model
12
Advancing innovative products by enabling access to a full range of incubation
‘ingredients’ supplied by network of strategic partners
J&J Innovation providing access to…
13
Working with us
• Deep Expertise
Fundamental understanding of basic science / biology
Comprehensive consumer and patients insights
Rapid assimilation of emerging research, clinical findings in development
• Vast Networks
Meaningful and sustained engagement in the regional ecosystem
Access the best and diverse scientific thinking of both internal and external
global experts.
Integrated diligence and development approach of internal and external experts
• Skin in the game
Conviction and closeness to asset
Personal accountability
Bottom up-driven product vision
Keep the innovation with the innovators
Key Components for Innovation
14
Understand our focus
J&J Innovation focuses on early stage business development
- Janssen is the collaboration partner for clinical trials and late-
stage collaboration
Know your science – and keep your business hat on
Original science comes first – and a clear commercialization plan
right at the tail
Practice the pitch and make it easy for us
Investors see 300+ companies per year. The first 5 minutes are
critical. Make us say ”wow, really?!”.
Working with us
15
16
Examples of academia-
industry collaboration
Discovery through collaboration and open innovation Exploring new pathways to develop first-in-class small molecule therapies in
immune-mediated diseases
• Project Leadership
• Lead Identification –
HTS (Discovery Sci.)
• PPI know how
• Medicinal Chemistry –
TA guided CRO
• Scientific Rationale for
IL-15 antagonists
• PsO, RA, IBD
• Tools and Assays
• Patient access
• Translational expertise
• IL-15 Know how and IP
• Tools and Assays
• Early NCE Hits
Case 1
• Encourage collaborative research
between the academia / research
institutes & Janssen R&D in
neurodegenerative disorders
• Janssen R&D collaborating with
academic institutions from Benelux
• Select projects funded; close
collaboration between academic project
lead and Janssen scientist
• Aim: novel treatment alternatives, better
disease models, patient identification
and stratification, and understanding of
disease mechanisms
Case 2
Wellcome Trust consortium for neuroinflammation in depression and Alzheimer’s disease
Initiative to undertake bioinformatics studies and a range of preclinical and clinical studies to identify
biomarkers and appropriate molecules to bring forward for clinical testing and to identify those patients who may be most suitable for this approach.
Case 3
En lysande idé kan komma varifrån helst
En lysende ide kan komme hvor som helst fra
En strålende idé kan komme alle steder fra
Frábæra hugmynd má fá hvar sem er
Loistava idea voi ilmestyä mistä vaan
• Conviction level of experts in science & target
• Ability to establish pre-clinical and clinical POC
• Time and cost to preclinical and clinical POC
• Leadership potential (competitive landscape)
• Strategic fit for J&J
• IP strength
• Collaboration capability of partner
• Patient impact (medical need)
• Societal impact (e.g., patient years)
• Transformative potential at time of launch
• Cost of access (deal terms)
What We Consider & How We Prioritize
22
Delivering
Clinical POC
products
A Closer Look at Our Pharmaceutical Therapy Areas
23
Cardiovascular and
Metabolism
– Type 2 Diabetes
– Heart Failure
Neuroscience
– Mood Disorders
– Alzheimer’s Disease
Infectious Diseases and
Vaccines
– Hepatitis
– Respiratory Infections
Immunology
– Rheumatoid Arthritis
– Inflammatory Bowl Disease
– Psoriasis
– Pulmonary
Oncology
– Prostate Cancer
– Lung Cancer
– Hematologic Malignancies
